Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 16Neoplasms 14Prostatic Neoplasms 10Hematologic Neoplasms 9Colorectal Neoplasms 8Lung Neoplasms 5Hematopoietic and Lymphatic System Neoplasm 5Squamous Cell Carcinoma of Head and Neck 4Anatomic Stage I Breast Cancer AJCC v8 4Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Melanoma 3Malignant Solid Neoplasm 3Leukemia, Myeloid, Acute 3Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urinary Bladder Neoplasms 2Sarcoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Parotid Neoplasms 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Head and Neck Carcinoma 2Glioma 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Basal Cell 2COVID-19 2

Interventions

olaparib 3enzalutamide 2darolutamide 2Prednisone 2Prednisolone 2Pluvicto 2Docetaxel 2Androgen Antagonists 2Abiraterone Acetate 2testosterone 17 beta-cypionate 1radium Ra 223 dichloride 1fludarabine phosphate 1fludarabine 1cabazitaxel 1alovudine 1abiraterone 1Standard of Care 1Radium-223 1PSMA-617 1Nivolumab 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × Standard of Care × 90 days × Clear all
NCT06401980 2026-03-30

Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Swiss Cancer Institute

Phase 2 Recruiting
162 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡